Blood Biomarkers for Detecting Brain Injury in COVID-19 Patients

COVID-19 can directly cause neurologic symptoms and long-term neurological disease. Elevations of blood biomarkers indicative of brain injury have been reported in the blood and cerebrospinal fluid of COVID-19 patients. Clinical application of blood biomarkers to improve medical management of COVID-19 patients is reported in the peer-reviewed Journal of Neurotrauma.

“The COVID-19 pandemic poses significant risks for acute and persistent neurological deficits, as well as possible increased risk for neurodegenerative diseases,” state Ronald Hayes, Ph.D., founder and chief scientific officer of UF startup and UF Innovate | Sid Martin Biotech alum Banyan Biomarkers, and coauthors. “The use of blood biomarkers of brain injury integrated with additional existing diagnostic tools with big dataset analytics could provide timely, cost-effective approaches to address this increasingly urgent unmet medical need.”

Learn more about Blood Biomarkers for Detecting Brain Injury in COVID-19 Patients.